Sort by
Keyphrases
Breast Cancer
100%
HPV16
85%
Tumor Antigen
85%
Tumor
77%
Autoantibodies
70%
High-risk Human Papillomavirus (HR-HPV)
66%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
60%
Ovarian Cancer
45%
Triple-negative Breast Cancer
41%
Early Detection
40%
Protein Microarray
36%
Immune Response
34%
Point-of-care
34%
Antibody Detection
33%
Epitope
33%
T Cells
31%
Prognostic Biomarker
30%
Enzyme-linked Immunosorbent Assay (ELISA)
29%
Human Telomerase Reverse Transcriptase (hTERT)
26%
Immunogenicity
25%
HLA-A2
24%
COVID-19
23%
Janus Kinase 2 (JAK2)
22%
Healthy Individuals
22%
Carbohydrate Antigen 125 (CA125)
22%
Cervical Cancer
22%
Programmed Death-ligand 1 (PD-L1)
22%
Vaccination
22%
Multiplexing
22%
Neoepitope
21%
Autoantibody Biomarker
20%
Antigen Processing
20%
Serum Antibody
20%
Cancer Patients
20%
Early Disease
19%
Bead Array
19%
Tumor Cells
18%
In Cancer
18%
Telomerase
18%
Multiplex Detection
18%
Proteomics
17%
Potential Biomarkers
17%
Early Breast Cancer
17%
MHC Class II
17%
HPV16 E7
16%
Cytotoxic T Lymphocytes
16%
CD8+ T Cells
16%
Risk Stratification
15%
Highly Sensitive
15%
Circulating Tumor DNA (ctDNA)
15%
Immunology and Microbiology
Epitope
81%
Tumor Antigen
62%
Autoantibodies
60%
Human Papillomavirus Type 16
59%
T Cell
57%
Peptides
49%
Wart Virus
41%
Immunity
40%
Immune Response
39%
Immunotherapy
34%
Proteomics
32%
Cytotoxic T Cell
28%
Protein Microarray
26%
Cytotoxic T-Cell
26%
Tumor Vaccine
25%
Neck
23%
ELISA
23%
P53
22%
Antigen Presentation
21%
Immunogenicity
21%
Enzyme-Linked Immunosorbent Assay
18%
Multiple Myeloma
18%
B Cell
16%
Cancer Immunotherapy
14%
Antigen Specificity
14%
Humoral Immunity
14%
Antigen-Presenting Cell
13%
Cytokine
13%
Squamous Cell
13%
Antibody Blood Level
13%
MHC Class I
12%
Amplicon
12%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Cell Mutant
12%
Reverse Transcriptase
12%
Lateral Flow Assay
12%
Allele
11%
Bioinformatics
11%
Autoimmunity
11%
Early Antigen
10%
Epidermal Growth Factor
10%
Dendritic Cell
9%
Infectious Agent
9%
Serology
8%
Tumor Cell
8%
Cell Line
8%
Immune System
8%
Immunoassay
8%
Blood Plasma
8%
Antibodies
8%
Medicine and Dentistry
Breast Cancer
99%
Biological Marker
61%
Human Papillomavirus Type 16
53%
Neoplasm
53%
Wart Virus
51%
Autoantibodies
41%
Diseases
39%
Ovarian Cancer
36%
Oropharynx Carcinoma
34%
Tumor Antigen
25%
Mammography
21%
Malignant Neoplasm
20%
Triple Negative Breast Cancer
19%
Cervical Cancer Screening
19%
Prevalence
18%
Protein Microarray
18%
Epitope
17%
Cervical Cancer
15%
Clinical Trial
14%
Cancer
14%
CA-125
14%
Prospective Study
14%
Sentinel Lymph Node Biopsy
13%
Breast Cancer Screening
12%
Health Care Cost
12%
Neoadjuvant Therapy
12%
Evolution
12%
Multiple Myeloma
12%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
CYP1B1
12%
Protein P53
12%
Metastatic Carcinoma
11%
Immune Response
11%
Enzyme Linked Immunosorbent Assay
11%
T Cell
11%
Head and Neck Cancer
10%
Breast Tumor
9%
Estrogen Receptor
9%
Immunotherapy
9%
Nucleic Acid
9%
Recurrent Disease
9%
Public Health
9%
Medical Care
9%
Lateral Flow Assay
9%
Disease Exacerbation
9%
Immunity
8%
Breast Carcinoma
8%
Early Antigen
8%
Cytotoxic T-Cell
8%
Infection
8%